Literature DB >> 1134518

A comparison of effectiveness of screening for phenylketonuria in the United States, United Kingdom and Ireland.

B Starfield, N A Holtzman.   

Abstract

A study of the effectiveness of screening for phenylketonuria in the United Kingdom, Ireland, and the United States indicated that the diagnosis is more likely to be missed in the latter two countries because of the earlier age at which infants are screened. Furthermore, in the United States, diagnosis and treatment are delayed as compared with Ireland and the United Kingdom. Because test most commonly used to detect phenylketonuria is identical in all three countries, the differences in effectiveness are attributable to the way in which it is applied. In the United Kingdom, personnel and facilities have clearly defined roles and responsibilities. There is co-ordination between in-hospital and extra-hospital health care, and follow-up care of young infants in the community is assured. Greater effectiveness of screening in the United States will require a more rational organization of health services.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1134518     DOI: 10.1056/NEJM197507172930304

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  4 in total

1.  The periodic health examination. Canadian Task Force on the Periodic Health Examination.

Authors: 
Journal:  Can Med Assoc J       Date:  1979-11-03       Impact factor: 8.262

2.  A clinician's view of the mass screening of the newborn for inherited diseases: current practice and future considerations.

Authors:  I B Sardharwalla; J E Wraith
Journal:  J Inherit Metab Dis       Date:  1989       Impact factor: 4.982

3.  Screening for congenital hypothyroidism in the Republic of Ireland.

Authors:  S Dockeray; S F Cahalane; M Brody; C Mullins; M J Cullen
Journal:  Br Med J       Date:  1980-12-06

4.  Presidential address: preventive medical practice.

Authors:  D L Rabin
Journal:  J Community Health       Date:  1981
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.